Literature DB >> 25516692

Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.

Maria Sorbera, Elizabeth Chung, Christopher W Ho, Nino Marzella.   

Abstract

Ceftolozane/tazobactam: a new option in the treatment of complicated gram-negative infections.

Entities:  

Year:  2014        PMID： 25516692      PMCID： PMC4264669     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  16 in total

1.  Progress and challenges in implementing the research on ESKAPE pathogens.

Authors:  Louis B Rice
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

2.  10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; Daniel K Benjamin; John Bradley; Robert J Guidos; Ronald N Jones; Barbara E Murray; Robert A Bonomo; David Gilbert
Journal:  Clin Infect Dis       Date:  2013-04-17       Impact factor: 9.079

Review 3.  Vaccine approaches for multidrug resistant Gram negative infections.

Authors:  Brian Campfield; Kong Chen; Jay K Kolls
Journal:  Curr Opin Immunol       Date:  2014-03-15       Impact factor: 7.486

4.  In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.

Authors:  Shinobu Takeda; Toru Nakai; Yoshimi Wakai; Fumiaki Ikeda; Kazuo Hatano
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

5.  Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.

Authors:  Bartolomé Moyá; Laura Zamorano; Carlos Juan; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

6.  Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

Authors:  Benjamin Miller; Ellie Hershberger; David Benziger; Mymy Trinh; Ian Friedland
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

7.  Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship.

Authors:  Rebecca R Roberts; Bala Hota; Ibrar Ahmad; R Douglas Scott; Susan D Foster; Fauzia Abbasi; Shari Schabowski; Linda M Kampe; Ginevra G Ciavarella; Mark Supino; Jeremy Naples; Ralph Cordell; Stuart B Levy; Robert A Weinstein
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

8.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.

Authors:  Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

9.  Acquired antibiotic resistance genes: an overview.

Authors:  Angela H A M van Hoek; Dik Mevius; Beatriz Guerra; Peter Mullany; Adam Paul Roberts; Henk J M Aarts
Journal:  Front Microbiol       Date:  2011-09-28       Impact factor: 5.640

Review 10.  Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination.

Authors:  Mai-Chi Hong; Donald I Hsu; Mark Bounthavong
Journal:  Infect Drug Resist       Date:  2013-11-29       Impact factor: 4.003
View more
  7 in total

1.  Neurological and Psychiatric Adverse Effects of Antimicrobials.

Authors:  Madison K Bangert; Rodrigo Hasbun
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

2.  Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates.

Authors:  María Milagro Montero; Sandra Domene-Ochoa; Carla López-Causapé; Inmaculada López-Montesinos; Sonia Luque; Luisa Sorlí; Núria Campillo; Eduardo Padilla; Núria Prim; Lorena Ferrer Alapont; Santiago Grau; Antonio Oliver; Juan P Horcajada
Journal:  Microbiol Spectr       Date:  2022-06-13

Review 3.  Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase Inhibitors.

Authors:  Anou M Somboro; John Osei Sekyere; Daniel G Amoako; Sabiha Y Essack; Linda A Bester
Journal:  Appl Environ Microbiol       Date:  2018-08-31       Impact factor: 4.792

4.  Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.

Authors:  George Sakoulas; Warren Rose; Andrew Berti; Joshua Olson; Jason Munguia; Poochit Nonejuie; Eleanna Sakoulas; Michael J Rybak; Joseph Pogliano; Victor Nizet
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model.

Authors:  María M Montero; Sandra Domene-Ochoa; Carla López-Causapé; Sonia Luque; Luisa Sorlí; Núria Campillo; Eduardo Padilla; Núria Prim; Lorena Ferrer-Alapont; Ariadna Angulo-Brunet; Santiago Grau; Antonio Oliver; Juan P Horcajada
Journal:  Sci Rep       Date:  2021-11-12       Impact factor: 4.379

6.  Evaluation of Carbapenem Use Before and After Implementation of an Antimicrobial Stewardship-Led Carbapenem-Sparing Strategy in a Lebanese Tertiary Hospital: A Retrospective Study.

Authors:  Mira El Masri; Nisrine Haddad; Therese Saad; Nesrine A Rizk; Ramia Zakhour; Souha S Kanj; Rony M Zeenny
Journal:  Front Cell Infect Microbiol       Date:  2022-03-25       Impact factor: 5.293

7.  Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 study.

Authors:  Felipe Francisco Tuon; Juliette Cieslinski; Suellen da Silva Rodrigues; Fernando Brandão Serra; Marina Della-Negra de Paula
Journal:  Braz J Infect Dis       Date:  2020-04-28       Impact factor: 3.257
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.